专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08828396B2 Silent Fc variants of anti-CD40 antibodies 有权
标题翻译：抗CD40抗体的沉默Fc变体
公开(公告)号：US08828396B2
公开(公告)日：2014-09-09
申请号：US13295141
申请日：2011-11-14
申请人： Christoph Heusser , James Rush , Karen Vincent
发明人： Christoph Heusser , James Rush , Karen Vincent
IPC分类号： A61K39/395 , C07K16/28 , A61K39/00
CPC分类号： C07K16/2878 , A61K2039/505 , C07K16/2866 , C07K2317/52 , C07K2317/565 , C07K2317/60 , C07K2317/71
摘要： The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.
摘要翻译：本发明涉及抗CD40抗体的沉默性Fc变体，以及所述抗体用于治疗诸如自身免疫性和炎症性疾病等病理性疾病和/或预防或降低移植排斥反应风险的组合物和方法。

2. 发明授权

US07053062B2 Compositions and methods for inducing gene expression 有权
公开(公告)号：US07053062B2
公开(公告)日：2006-05-30
申请号：US10190394
申请日：2002-07-03
申请人： Richard J. Gregory , Karen Vincent
发明人： Richard J. Gregory , Karen Vincent
IPC分类号： A61K31/70 , C12N15/00 , C12N15/63 , C07H21/04
CPC分类号： C12N15/85 , A61K38/00 , A61K48/00 , C07K14/4702 , C07K14/52 , C07K2319/00 , C07K2319/71 , C07K2319/80 , C12N2799/022
摘要： The present invention provides recombinant nucleic acid molecules encoding a chimeric transactivator protein including a DNA binding domain of a DNA binding protein and a protein domain capable of transcriptional activation. The present invention also provides recombinant viral and non-viral vectors that are able to infect and/or transfect and sustain expression of a biologically active chimeric transactivator proteins in mammalian cells. Also provided are host cell lines and non-human transgenic animals capable of expressing biologically active chimeric transactivator proteins. In another aspect, compositions and methods for treating or preventing ischemic damage associated with hypoxia-related disorders are provided.

3. 发明授权

US06632670B1 AAV vectors for gene therapy 有权
标题翻译：用于基因治疗的AAV载体
公开(公告)号：US06632670B1
公开(公告)日：2003-10-14
申请号：US09029705
申请日：1998-11-16
申请人： Samuel C. Wadsworth , Karen Vincent , Susan Piraino , Sirkka Kyostio
发明人： Samuel C. Wadsworth , Karen Vincent , Susan Piraino , Sirkka Kyostio
IPC分类号： C12N15864
CPC分类号： C12N7/00 , A01K2217/05 , A61K48/00 , C12N15/86 , C12N2750/14143 , C12N2750/14152
摘要： The present invention is directed to methods for generating high titer, contaminant free, recombinant AAV vectors, methods and genetic constructs for producing recombinant AAV vectors conveniently and in large quantities, methods for the delivery of all essential viral proteins required in trans for high yields of recombinant AAV, recombinant AAV vectors for use in gene therapy, novel packaging cell lines which obviate the need for cotransfection of vector and helper plasmids, helper plasmids and vector plasmid backbone constructs, a reporter assay for determining AAV vector yield. Further provided are recombinant AAV vectors in a pharmaceutically acceptable carrier, methods of delivering a transgene of interest to a cell, compositions and methods for delivering a DNA sequence encoding a desired polypeptide to a cell, and transgenic non-human mammals that express a human chromosome 19 AAV integration locus.
摘要翻译：本发明涉及用于产生高效价，无污染的重组AAV载体的方法，用于方便和大量生产重组AAV载体的方法和遗传构建体，用于递送反式所需的所有必需病毒蛋白的高产率的方法重组AAV，用于基因治疗的重组AAV载体，新型包装细胞系，其不需要共转染载体和辅助质粒，辅助质粒和载体质粒骨架构建体，用于测定AAV载体产量的报道分析。还提供了药学上可接受的载体中的重组AAV载体，将感兴趣的转基因递送至细胞的方法，用于将编码所需多肽的DNA序列递送至细胞的组合物和方法，以及表达人染色体的转基因非人哺乳动物 19 AAV整合轨迹。

4. 发明申请

US20130064823A1 COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC LOW DENSITY LIPOPROTEIN - RELATED PROTEIN 6 (LRP6) MULTIVALENT ANTIBODIES 有权
标题翻译：用于治疗性低密度脂蛋白相关蛋白6（LRP6）多种抗体的组合物和方法
公开(公告)号：US20130064823A1
公开(公告)日：2013-03-14
申请号：US13696372
申请日：2011-05-05
申请人： Feng Cong , Seth Ettenberg , David Jenkins , Ming Lei , Andreas Loew , Karen Vincent , Li Zhou
发明人： Feng Cong , Seth Ettenberg , David Jenkins , Ming Lei , Andreas Loew , Karen Vincent , Li Zhou
IPC分类号： C07K16/46 , A61P35/02 , A61K39/395 , A61P35/00 , C12N15/13 , C12N15/63
CPC分类号： C07K16/2863 , A61K39/395 , A61K39/3955 , A61K2039/505 , C07K16/28 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/35 , C07K2317/55 , C07K2317/622 , C07K2317/64 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00
摘要： The present disclosure relates to an antibody or antigen binding fragment having at least two receptor binding do mains for two different binding sites of LRP6 and compositions and methods of use thereof.
摘要翻译：本公开内容涉及具有至少两个受体结合的抗体或抗原结合片段，其用于LRP6的两个不同结合位点和组合物及其使用方法。

5. 发明申请

US20160152721A1 SILENT Fc VARIANTS OF ANTI-CD40 ANTIBODIES 审中-公开
标题翻译：抗CD40抗体的静电Fc变体
公开(公告)号：US20160152721A1
公开(公告)日：2016-06-02
申请号：US14946170
申请日：2015-11-19
申请人： Christoph HEUSSER , James RUSH , Karen VINCENT
发明人： Christoph HEUSSER , James RUSH , Karen VINCENT
IPC分类号： C07K16/28
CPC分类号： C07K16/2878 , A61K2039/505 , C07K16/2866 , C07K2317/52 , C07K2317/565 , C07K2317/60 , C07K2317/71
摘要： The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.
摘要翻译：本发明涉及抗CD40抗体的沉默性Fc变体，以及所述抗体用于治疗诸如自身免疫性和炎症性疾病等病理性疾病和/或预防或降低移植排斥反应风险的组合物和方法。

6. 发明授权

US09290573B2 Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies 有权
标题翻译：治疗性低密度脂蛋白相关蛋白6（LRP6）多价抗体
公开(公告)号：US09290573B2
公开(公告)日：2016-03-22
申请号：US13696372
申请日：2011-05-05
申请人： Feng Cong , Seth Ettenberg , David Jenkins , Ming Lei , Andreas Loew , Karen Vincent , Li Zhou
发明人： Feng Cong , Seth Ettenberg , David Jenkins , Ming Lei , Andreas Loew , Karen Vincent , Li Zhou
IPC分类号： C07K16/28 , C07K16/46 , A61K39/395 , A61K39/00
CPC分类号： C07K16/2863 , A61K39/395 , A61K39/3955 , A61K2039/505 , C07K16/28 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/35 , C07K2317/55 , C07K2317/622 , C07K2317/64 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00
摘要： The present disclosure relates to an antibody or antigen binding fragment having at least two receptor binding domains for two different binding sites of LRP6 and compositions and methods of use thereof.
摘要翻译：本公开涉及具有至少两个LRP6的两个不同结合位点的受体结合结构域的抗体或抗原结合片段及其组合物及其使用方法。

7. 发明申请

US20140341898A1 SILENT Fc VARIANTS OF ANTI-CD40 ANTIBODIES 审中-公开
标题翻译：抗CD40抗体的静电Fc变体
公开(公告)号：US20140341898A1
公开(公告)日：2014-11-20
申请号：US14452647
申请日：2014-08-06
申请人： Christoph HEUSSER , James RUSH , Karen VINCENT
发明人： Christoph HEUSSER , James RUSH , Karen VINCENT
IPC分类号： C07K16/28
CPC分类号： C07K16/2878 , A61K2039/505 , C07K16/2866 , C07K2317/52 , C07K2317/565 , C07K2317/60 , C07K2317/71
摘要： The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.
摘要翻译：本发明涉及抗CD40抗体的沉默性Fc变体，以及所述抗体用于治疗诸如自身免疫性和炎症性疾病等病理性疾病和/或预防或降低移植排斥反应风险的组合物和方法。

8. 发明申请

US20060127361A1 Compositions and methods for inducing gene expression 审中-公开
公开(公告)号：US20060127361A1
公开(公告)日：2006-06-15
申请号：US11352879
申请日：2006-02-13
申请人： Richard Gregory , Karen Vincent
发明人： Richard Gregory , Karen Vincent
IPC分类号： A61K48/00 , C07H21/04
CPC分类号： C12N15/85 , A61K38/00 , A61K48/00 , C07K14/4702 , C07K14/52 , C07K2319/00 , C07K2319/71 , C07K2319/80 , C12N2799/022
摘要： The present invention provides recombinant nucleic acid molecules encoding a chimeric transactivator protein including a DNA binding domain of a DNA binding protein and a protein domain capable of transcriptional activation. The present invention also provides recombinant viral and non-viral vectors that are able to infect and/or transfect and sustain expression of a biologically active chimeric transactivator proteins in mammalian cells. Also provided are host cell lines and non-human transgenic animals capable of expressing biologically active chimeric transactivator proteins. In another aspect, compositions and methods for treating or preventing ischemic damage associated with hypoxia-related disorders are provided.

9. 发明授权

US09221913B2 Silent Fc variants of anti-CD40 antibodies 有权
标题翻译：抗CD40抗体的沉默Fc变体
公开(公告)号：US09221913B2
公开(公告)日：2015-12-29
申请号：US14452647
申请日：2014-08-06
申请人： Christoph Heusser , James Rush , Karen Vincent
发明人： Christoph Heusser , James Rush , Karen Vincent
IPC分类号： A61K39/395 , C07K16/28 , A61K39/00
CPC分类号： C07K16/2878 , A61K2039/505 , C07K16/2866 , C07K2317/52 , C07K2317/565 , C07K2317/60 , C07K2317/71
摘要： Anti-CD40 antibodies have not been reported to induce hemostatic events in patients, however elevations in pancreatic enzymes in B cell lymphoma patients receiving the anti-CD40 Ab Chir12.12 and the possible risk of pancreatitis precludes the use of this Fc-competent anti-CD40 antibody in chronic autoimmune disease and transplantation for safety reasons. We therefore generated Fc-silent IgG1 anti-CD40 antibodies (mAb1, mAb2 and mAb3) unable to mediate antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) both in vitro and in vivo. mAb1 was able to prolong non-human primate renal allograft survival in combination with sub-therapeutic doses of cyclosporine. In addition, mAb1 was able to completely suppress primary and secondary antibody responses to immunization with a T cell-dependent antigen. Crucially, there was no evidence of hemostatic events or abnormal pancreatic histology in either the transplant or immunization study. Collectively these results suggest mAb1 would be a safe and efficacious therapeutic, and could be used to treat patients suffering from B lymphocyte and antigen presenting cell driven autoimmune disease or undergoing allograft transplant where CD4O-CD154 interactions are involved in contributing to pathology.
摘要翻译：抗CD40抗体尚未报道在患者中诱导止血事件，但是接受抗CD40 Ab Chir12.12的B细胞淋巴瘤患者胰腺酶升高以及胰腺炎的可能风险可能导致使用此抗Fc抗体抗体， CD40抗体在慢性自身免疫性疾病和移植中的安全性原因。因此，我们在体外和体内产生了不能介导抗体依赖性细胞毒性（ADCC）或补体依赖性细胞毒性（CDC）的Fc-沉默IgG1抗CD40抗体（mAb1，mAb2和mAb3）。 mAb1与亚治疗剂量的环孢菌素组合能够延长非人灵长类动物肾同种异体移植物存活。此外，mAb1能够完全抑制用T细胞依赖性抗原免疫的一抗和二抗。至关重要的是，在移植或免疫研究中没有止血事件或异常胰组织学的迹象。总体而言，这些结果表明，mAb1将是一种安全有效的治疗方法，可用于治疗患有B淋巴细胞和抗原呈递细胞驱动的自身免疫性疾病或进行同种异体移植的患者，其中CD4O-CD154相互作用涉及病理学。

10. 发明申请

US20120121585A1 SILENT Fc VARIANTS OF ANTI-CD40 ANTIBODIES 有权
标题翻译：抗CD40抗体的静电Fc变体
公开(公告)号：US20120121585A1
公开(公告)日：2012-05-17
申请号：US13295141
申请日：2011-11-14
申请人： Christoph HEUSSER , James RUSH , Karen VINCENT
发明人： Christoph HEUSSER , James RUSH , Karen VINCENT
IPC分类号： A61K39/395 , C12N15/13 , C12N15/63 , C12P21/02 , A61P25/00 , C12N1/19 , C12N1/15 , A61P37/06 , A61P29/00 , C07K16/28 , C12N5/10
CPC分类号： C07K16/2878 , A61K2039/505 , C07K16/2866 , C07K2317/52 , C07K2317/565 , C07K2317/60 , C07K2317/71
摘要： The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.
摘要翻译：本发明涉及抗CD40抗体的沉默性Fc变体，以及所述抗体用于治疗诸如自身免疫性和炎症性疾病等病理性疾病和/或预防或降低移植排斥反应风险的组合物和方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式